Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
IOPAMIDOL-250 vs IOPAMIDOL-250 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent